10-K: ALX Oncology Reports Positive Phase 2 Data, Plans New Clinical Trials in 10-K Filing

ALX Oncology's 10-K filing highlights positive Phase 2 clinical data for evorpacept and outlines plans for new clinical trials in breast and colorectal cancer.

Summary

• ALX Oncology, a clinical-stage immuno-oncology company, is focused on developing therapies that block the CD47 immune checkpoint.
• Their lead product candidate, evorpacept, is currently in multiple Phase 1 and 2 clinical trials.
• Evorpacept is designed to have a high affinity for CD47 and to avoid hematologic toxicities.
• The ASPEN-06 Phase 2 clinical trial evaluated evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel (Evo-TRP) versus trastuzumab, ramucirumab, and paclitaxel (TRP) in HER2-positive gastric/GEJ cancer patients.
• In the ITT patient population, Evo-TRP demonstrated an ORR of 41.3% compared to 26.6% for TRP control.
• In patients with fresh HER2-positive biopsies, Evo-TRP demonstrated an ORR of 59.1% compared to 23.1% for TRP control.
• The mDOR in the ITT population was 15.7 months for Evo-TRP and 9.1 months for TRP.
• The mPFS in the ITT population was 7.5 months for Evo-TRP and 6.7 months for TRP, with a PFS HR of 0.64.
• The company intends to initiate a Phase 2 study evaluating evorpacept in combination with trastuzumab and chemotherapy for metastatic HER2-positive breast cancer.
• A Phase 1b study evaluating evorpacept in combination with cetuximab and chemotherapy for metastatic CRC is also planned.
• The company expects to file an IND for ALX2004, their first ADC program, in the first quarter of 2025.
• As of December 31, 2024, the company had cash, cash equivalents, and investments of $131.3 million, which is expected to fund operations into the fourth quarter of 2026.
• The company's net losses were $134.9 million, $160.8 million and $123.5 million for the years ended December 31, 2024, 2023 and 2022, respectively.
• As of December 31, 2024, the company had 80 employees, 30 of whom hold Ph.D. or M.D. degrees and 64 of whom were engaged in research and development activities.

Sentiment

Score: 7

Explanation: The document presents positive clinical data and outlines plans for future development, but also acknowledges the company's financial challenges and competitive landscape. The sentiment is cautiously optimistic.

Positives

• Positive Phase 2 clinical data from the ASPEN-06 trial supports the clinical validation of evorpacept's mechanism of action.
• Evorpacept was generally well tolerated in the ASPEN-06 trial, with adverse events consistent with the TRP control arm.
• The company has multiple ongoing clinical trials and collaborations, indicating a broad development plan for evorpacept.
• The company has a strong management team with experience in drug development and commercialization.
• The company has a solid cash position to fund operations into the fourth quarter of 2026.
• The company is developing a pipeline of innovative therapeutics based on their protein engineering expertise.
• The company has strategic partnerships to broaden the potential impact of their product candidates.
• The company has received Fast Track designation and Orphan Drug Designation from the FDA for evorpacept in certain indications.

Negatives

• The company has incurred significant net losses since its inception and expects to continue to incur significant net losses for the foreseeable future.
• The company has no products approved for commercial sale and has not generated any revenue from product sales, licenses, or collaborations.
• The company is substantially dependent on the success of its lead product candidate, evorpacept, which is in clinical development and has not completed a pivotal trial.
• Clinical trials are expensive, time-consuming, and difficult to design and implement and may fail to demonstrate adequate safety, efficacy, and potency of the company's product candidates.
• The company faces substantial competition from other companies developing immuno-oncology therapies.
• The company relies on third-party manufacturers for clinical supplies of its product candidates.
• The company's levels of debt and compliance with the terms of its loan agreement could restrict its ability to operate its business.

Risks

• The company may require substantial additional capital to finance its operations, and such capital may not be available when needed or may only be available on terms that are unfavorable.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• If the company is unable to obtain, maintain, and enforce patent protection and other intellectual property for its product candidates and related technology, its business could be materially harmed.
• The company is highly dependent on its key personnel, and if it is not successful in attracting, motivating, and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.
• The outbreaks or public health crises, such as the COVID-19 pandemic, geopolitical unrest related to Russia's war with Ukraine, and war and instability in Israel and the surrounding region could adversely impact the company's business including its ongoing and planned clinical trials and preclinical research.
• The price of the company's stock may be volatile, and investors could lose all or part of their investment.
• The company has identified material weaknesses in its internal control over financial reporting in the past, and if it is unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in its financial reports.

Future Outlook

The company believes that its existing cash, cash equivalents, and investments will be sufficient to fund its operations into the fourth quarter of 2026. The company plans to continue advancing the clinical development of evorpacept and its other programs.

Management Comments

• Our team of industry veterans plans to continue to advance a broad development plan for evorpacept that balances speed to market, scale of unmet need and existing clinical evidence for evorpacepts combination mechanisms.
• Members of our management team have brought multiple drugs to the FDA approval.

Industry Context

The company competes in the immuno-oncology market, which is highly competitive. Several other companies are developing therapies targeting the CD47 pathway. The company believes that evorpacept has differentiated properties that may allow it to overcome the limitations of other CD47 blocking agents.

Comparison to Industry Standards

• The document mentions several competitors developing drugs targeting the CD47 pathway, including Adagene, Akesobio, Boehringer Ingelheim, Bristol Myers Squibb, and Gilead Sciences (through its acquisition of Forty Seven).
• The document compares evorpacept to other CD47 blocking agents, highlighting its broader therapeutic window, strong potential for combination with other anti-cancer agents, encouraging responses in solid tumors, and broader potential indications.
• The document mentions that other CD47 blocking agents have failed to achieve meaningful clinical activity in the treatment of solid tumors.
• The document compares the unconfirmed ORR of 59% (n=22) with evorpacept plus EV in the ASPEN-07 trial to the EV single agent ORR benchmark of 41%.

Management Changes

Related Party Transactions

• The document mentions a research and development services agreement with Tallac Therapeutics, Inc.
• The document mentions a collaboration agreement with Tallac Therapeutics, Inc.
• The document mentions a milestone payment to ScalmiBio stockholders, including payments to the company's former Chief Executive Officer and another employee.

Stakeholder Impact

• Shareholders: The document provides information about the company's financial performance, clinical trial results, and future plans, which may impact the value of their investment.
• Employees: The document mentions a reduction in the company's workforce, which will impact employees.
• Patients: The document discusses the development of new cancer therapies, which may benefit patients in the future.
• Creditors: The document provides information about the company's debt obligations, which may impact creditors.

Next Steps

• Initiate a Phase 2 study evaluating evorpacept in combination with trastuzumab and chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer.
• Initiate a Phase 1b study evaluating evorpacept in combination with cetuximab and chemotherapy for the treatment of patients with metastatic CRC.
• File an IND for ALX2004, their first ADC program, in the first quarter of 2025.

Key Dates

Keywords

evorpacept, CD47, oncology, clinical trials, immunotherapy, cancer, ALX Oncology, ASPEN-06, HER2, GEJ, HNSCC